Novo Nordisk A/S (NOV)
XETR
Closed
Aug 25, 2026
Day's Range
40.6952 wk Range
30.23Overview - NOV - Novo Nordisk A/S
Key Statistics
Valuation
Enterprise Value
36.49B
P/E (Trailing)
‪11.43‬
PEG Ratio
‪-0.55‬
Price / Sales (TTM)
‪0.53‬
Price / Book
‪6.00‬
EV / EBITDA
‪1.57‬
Profitability
Gross Margin
‪78.21%‬
Profit Margin
‪35.34%‬
Operating Margin
‪42.54%‬
Return on Assets
‪18.72%‬
Return on Equity
‪59.81%‬
Ownership
Shares Outstanding
4.42B
Float
3.17B
Held by Insiders
‪5.28%‬
Held by Institutions
‪33.32%‬
Price stats
Beta
‪0.34‬
50-Day Avg
‪41.65‬
200-Day Avg
‪39.96‬
Dividends
Payout Ratio
‪44.57%‬
Frequency
Semi-Annual
Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Peers - NOV - Novo Nordisk A/S
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on XETR.
Profile Summary - NOV - Novo Nordisk A/S
About
Novo Nordisk A/S is a global pharmaceutical company specializing in research, development, and manufacturing of treatments for serious chronic diseases. Founded through the 1989 merger of Danish insulin pioneers Nordisk Insulaboratorium and Novo Terapeutisk Laboratorium, it traces its roots to 1923 when commercial…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
